Publications by authors named "Thomas Lin"

Claim this Profile
D
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Laahn Foster, Larry D Anderson, Alfred Chung, Chakra P Chaulagain, Erin Pettijohn, Caitlin Costello, Huiling Pei, Thomas S Lin

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
Ashraf Badros, Laahn Foster, Larry D Anderson, Chakra P Chaulagain, Erin Pettijohn, Caitlin Costello, Huiling Pei, Thomas S Lin

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Caitlin Costello, Huiling Pei, Thomas S Lin

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Caitlin Costello, Huiling Pei, Thomas S Lin

Am J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Caitlin Costello, Huiling Pei, Thomas S Lin

Blood Cancer J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Huiling Pei, Thomas S Lin

Br J Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Caitlin Costello, Huiling Pei, Thomas S Lin

Blood Cancer J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Caitlin Costello, Huiling Pei, Thomas S Lin

Lancet Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aci-bench: a Novel Ambient Clinical Intelligence Dataset for Benchmarking Automatic Visit Note Generation.
Wen-Wai Yim, Yujuan Fu, Asma Ben Abacha, Neal Snider, Thomas Lin

Sci Data· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.
Scott A Soefje, Corinne Carpenter, Katherine Carlson, Samir Awasthi, Thomas S Lin

JCO Oncol Pract· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Caitlin Costello, Huiling Pei, Thomas S Lin

Transplant Cell Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Huiling Pei, Thomas S Lin

Future Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A Efebera, Huiling Pei, Thomas S Lin

Br J Haematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke, Thomas S Lin

Leuk Lymphoma· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Andrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, Huiling Pei, Patrick Lefebvre, Thomas S Lin

Oncologist· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Huiling Pei, Thomas S Lin

Blood Cancer J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaussian graphical modeling of the serum exposome and metabolome reveals interactions between environmental chemicals and endogenous metabolites.
Vincent Bessonneau, Roy R Gerona, Jessica Trowbridge, Rachel Grashow, Thomas Lin

Sci Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.
Peter M Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J Costa, Huiling Pei, Thomas S Lin

Blood Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.
Andrew D Zelenetz, Leslie L Popplewell, Ariela Noy, Thierry J Horner, Thomas S Lin

Clin Lymphoma Myeloma Leuk· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Peter M Voorhees, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Caitlin Costello, Huiling Pei, Thomas S Lin

Blood· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Exposure Knowledge and Serum Suspect Screening as a New Approach to Biomonitoring: An Application in Firefighters and Office Workers.
Rachel Grashow, Vincent Bessonneau, Roy R Gerona, Aolin Wang, Jessica Trowbridge, Thomas Lin

Environ Sci Technol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure to Perfluoroalkyl Substances in a Cohort of Women Firefighters and Office Workers in San Francisco.
Jessica Trowbridge, Roy R Gerona, Thomas Lin, Ruthann A Rudel, Vincent Bessonneau

Environ Sci Technol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke, Thomas S Lin

Br J Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Ajai Chari, Sagar Lonial, Tomer M Mark, Amrita Y Krishnan, Keith E Stockerl-Goldstein, Thomas S Lin

Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Suspect Screening Method for Characterizing Multiple Chemical Exposures among a Demographically Diverse Population of Pregnant Women in San Francisco.
Aolin Wang, Roy R Gerona, Jackie M Schwartz, Thomas Lin, Marina Sirota

Environ Health Perspect· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis